Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: ugai h. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
Nakamura K, Fujimoto K, Hasegawa C, Aoki I, Yoshitsugu H, Ugai H, Yatsuzuka N, Tanaka Y, Furihata K, Maas BM, Wickremasingha PK, Duncan KE, Iwamoto M, Stoch SA, Uemura N. Nakamura K, et al. Among authors: ugai h. Clin Transl Sci. 2022 Nov;15(11):2697-2708. doi: 10.1111/cts.13395. Epub 2022 Sep 23. Clin Transl Sci. 2022. PMID: 36053806 Free PMC article. Clinical Trial.
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Inoue Y, et al. Among authors: ugai h. Respir Med. 2021 Oct;187:106574. doi: 10.1016/j.rmed.2021.106574. Epub 2021 Aug 12. Respir Med. 2021. PMID: 34564020 Free article. Clinical Trial.
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.
Higaki J, Komuro I, Shiki K, Ugai H, Taniguchi A, Ikeda H, Kuroki D, Nishimura S, Ogihara T. Higaki J, et al. Among authors: ugai h. Hypertens Res. 2017 Jan;40(1):51-60. doi: 10.1038/hr.2016.100. Epub 2016 Sep 1. Hypertens Res. 2017. PMID: 27581533 Free PMC article. Clinical Trial.
Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T, Misawa S, Nakagawa S, Tanaka S, Tanase T, Ugai H, Wakana A, Yodo Y, Tsuchiya S, Suganami H; JPMA Task Force Members. Hasegawa T, et al. Among authors: ugai h. Pharm Stat. 2020 Jul;19(4):436-453. doi: 10.1002/pst.2004. Epub 2020 Feb 18. Pharm Stat. 2020. PMID: 32072769
63 results